Presentation is loading. Please wait.

Presentation is loading. Please wait.

Levocetirizine better protects than desloratadine in a nasal provocation with allergen  Cédric Deruaz, MD, Annette Leimgruber, MD, Monika Berney, Estelle.

Published byDaniel Thomas Modified over 5 years ago

Similar presentations

Presentation on theme: "Levocetirizine better protects than desloratadine in a nasal provocation with allergen  Cédric Deruaz, MD, Annette Leimgruber, MD, Monika Berney, Estelle."— Presentation transcript:

1 Levocetirizine better protects than desloratadine in a nasal provocation with allergen 
Cédric Deruaz, MD, Annette Leimgruber, MD, Monika Berney, Estelle Pradervand, François Spertini, MD  Journal of Allergy and Clinical Immunology  Volume 113, Issue 4, Pages (April 2004) DOI: /j.jaci

2 Fig 1 Cumulative number of patients reaching the global threshold according to the dose level of grass pollen allergen. Inset, Difference (Δ) in allergen dose level necessary to reach the threshold for each of the 24 patients between levocetirizine and desloratadine (in favor of levocetirizine, >0; in favor of desloratadine, <0). Plain vertical line, Mean Δ allergen dose level. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

3 Fig 2 Cumulative number of patients reaching the threshold according to the dose level of grass pollen allergen (X axis) for sneezes (A), secretions (B), PNIF (C), and MCA (D). In Fig 2, C and D, 24H corresponds to the 24-hour time point after the NPT. Insets, results are expressed as described in Fig 1. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

4 Fig 3 Concentration of albumin (A) and tryptase (B) in nasal lavage fluid at baseline (sample 1), after the dose of 33,000 SQs of allergen (sample 2), and 24 hours after the NPT (sample 3). Data are expressed as means±SDs. ∗Levocetirizine versus placebo, P<.05. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

5 Fig 4 Concentration of the late-phase inflammatory mediators IL-4 (A), IL-5 (B), IL-8 (C), and eotaxin (D) in nasal lavage fluid at baseline (sample 1), after the dose of 33,000 SQs of allergen (sample 2), and 24 hours after the NPT (sample 3). Data are expressed as means±SDs. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

6 Fig 5 Eosinophil count (A) and ECP concentration (B) in nasal lavage fluid at baseline (sample 1), after the dose of 33,000 SQs of allergen (sample 2), and 24 hours after the NPT (sample 3). Data are expressed as means±SDs. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

Download ppt "Levocetirizine better protects than desloratadine in a nasal provocation with allergen  Cédric Deruaz, MD, Annette Leimgruber, MD, Monika Berney, Estelle."

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Nasal challenge with allergen leads to maxillary sinus inflammation
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,

The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,
Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses  Chris J. Corrigan, MD, PhD, Wei.

Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses  Chris J. Corrigan, MD, PhD, Wei.
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
Role of nasal nitric oxide in the resolution of experimental rhinovirus infection  Scherer P Sanders, PhD, David Proud, PhD, Solbert Permutt, MD, Edward.

Role of nasal nitric oxide in the resolution of experimental rhinovirus infection  Scherer P Sanders, PhD, David Proud, PhD, Solbert Permutt, MD, Edward.
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.
The Editors' Choice Journal of Allergy and Clinical Immunology

The Editors' Choice Journal of Allergy and Clinical Immunology
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D.

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D.
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms  Natasha C. Gunawardana,

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms  Natasha C. Gunawardana,
Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen  Maria-Helena Terrien, MD, François Rahm, MD, Jean-Marc.

Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen  Maria-Helena Terrien, MD, François Rahm, MD, Jean-Marc.
Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses  Chris J. Corrigan, MD, PhD, Wei.

Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses  Chris J. Corrigan, MD, PhD, Wei.
As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis  Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis  Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,
Keith J. Simons, PhD, Margherita Strolin Benedetti, PhD, F. Estelle R

Keith J. Simons, PhD, Margherita Strolin Benedetti, PhD, F. Estelle R

Similar presentations

Ads by Google